Who we are

 

GliaPharm is a Swiss biotechnology company that develops treatments for neurological and psychiatric disorders.

 

GliaPharm’s innovative therapeutic approach is to target glial cells, the ‘support cells’ of neurons, to sustain their function and survival, and enhance brain metabolism in pathological conditions. We aim at developing new drugs that target glia-mediated pathways as agents for neuroprotection and maintenance of cognitive functions.

ContactTeam

About us

 

GliaPharm is a Swiss biotechnology company that develops innovative approaches to treat neurological and psychiatric disorders by targeting glial cells in the brain, a type of cell that is critical for neuroprotection and brain metabolism.

 

GliaPharm was created in 2016 as a spinoff company of three decades of research performed in the laboratory of Prof. Pierre Magistretti at Ecole Polytechnique Fédérale de Lausanne (EPFL, Switzerland), a leading research laboratory in the field of brain metabolism and glial cell biology.
In 2017, GliaPharm has established its laboratory at the Campus Biotech in Geneva, Switzerland.
Through its in-house R&D laboratory and network with selective partners, GliaPharm provides the necessary platform to develop clinical applications through mode of actions targeting glial cells.

Science

 

GliaPharm’s pioneering approach is to stimulate the neuroprotective action of glial cells to treat certain types of neurological and psychiatric disorders. These pathologies, which all share similar glial and metabolic dysfunctions, include the orphan neurometabolic disease GLUT1 deficiency syndrome (GLUT-DS, also known as De Vivo disease), Alzheimer’s disease, amyotrophic lateral sclerosis (ALS) and depression.

While the importance of glial cells has been overlooked in drug development so far, it is now clear that these cells play a key role in sustaining brain function and neuroprotection. Targeting glial cells hence represents an innovative approach for the treatment of neurological and psychiatric disorders based on strong scientific evidence.

GliaPharm has established a proprietary drug discovery platform, GliaX™, centered on glial cells activity and brain metabolism. Through this platform, the company is developing its pipeline program to establish a new class of agents for neuroprotection and maintenance of cognitive functions. GliaX™ also serves collaboration with academic and industrial partners.

Management Team

Dr. SYLVAIN LENGACHER, PhD

Co-chief executive officer, co-founder

AMBROISE MAGISTRETTI

Co-chief executive officer, co-founder

Dr. CHARLES FINSTERWALD, PhD

Chief scientific officer, co-founder

Advisors

Scientific Advisory Board

PROF. PIERRE J. MAGISTRETTI, MD, PhD

Chairman of the scientific advisory board

and co-founder

PROF. CRISTINA M. ALBERINI, PhD

Specialist in memory and cognition

PROF. YVES AGID, MD, PhD

Specialist in neurodegeneratic diseases

PROF. ANDREA VOLTERRA, PhD

Thought leader in glial biology

News

March 2021 – Innosuisse support

GliaPharm receives support from Innosuisse for a project to develop specific cell therapy to treat neurological diseases in collaboration with Universities of Bern and Lausanne


January 2021 – HEPIA collaboration

GliaPharm receives grant for collaboration with HEPIA to setup a new 3D culture method using brain organoids from mouse and human-derived cells


September 2020 – European Congress of Neuropsychopharmacology

GliaPharm to present at the European Congress of Neuropsychopharmacology – Symposium on “Beyond the Neurocentric Paradigm: Targeting Astrocytes and Neuroglial Interactions in CNS Disorders”. September 13th 2020.


August 2020 – #FOXG1

GliaPharm to present at the virtual #FOXG1ScienceSymposium on August 17/18. Register here to tune in to hear from all the researchers, industry and more about the path to a cure for #FOXG1. #FOXG1SS2020


August 2020 – LifeSci Symposium

GliaPharm presented at the LifeSci Partners Summer Symposium on August 5th 2020


May 2020 – CHF 2 Million financing

GliaPharm completes a CHF 2 Million financing to advance its drug development program for an orphan neurological disease




Recent publications

ULTRASTRUCTURAL EVIDENCE FOR A ROLE OF ASTROCYTES AND GLYCOGEN-DERIVED LACTATE IN LEARNING-DEPENDENT SYNAPTIC STABILIZATION

Vezzoli E, Cali C, De Roo M, Ponzoni L, Sogne E, Gagnon N, Francolini M, Braida D, Sala M, Muller D, Falqui A, Magistretti PJ

Cereb Cortex. 2020 Apr 14;30(4):2114-2127. doi: 10.1093/cercor/bhz226.

https://academic.oup.com/cercor/article/30/4/2114/5625994


EXCITATION STATES OF METABOLIC NETWORKS PREDICT DOSE-RESPONSE FINGERPRINTING AND LIGAND PULSE PHASE SIGNALLING

Coggan JS, Keller D, Markram H, Schurmann F, Magistretti PJ

J Theor Biol. 2020 Feb 21;487:110123. doi: 10.1016/j.jtbi.2019.110123

https://www.sciencedirect.com/science/article/pii/S0022519319304928?via%3Dihub


LACTATE AND PYRUVATE PROMOTE OXIDATIVE STRESS RESISTANCE THROUGH HORMETIC ROS SIGNALING

Tauffenberger A, Fiumelli H, Alsmustafa S, Magistretti PJ

Cell Death Dis. 2019. PMID: 31506428

https://www.nature.com/articles/s41419-019-1877-6

Our Partners